Effects of particle size and adding sequence of fine lactose on the deposition of salbutamol sulphate from a dry powder formulation

International Journal of Pharmaceutics

Volumn 182, Issue 2, 1999, Pages 133-144

  Zeng, Xian Ming ^a   Martin, Gary Peter ^a   Tee, Seah Kee ^a   Ghoush, Abeer Abu ^a   Marriott, Christopher ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Deposition; Dispersion; Dry powder inhalers; Lactose; Salbutamol sulphate; Ternary mixes

Indexed keywords

LACTOCHEM; LACTOSE; SALBUTAMOL; SALBUTAMOL SULFATE; UNCLASSIFIED DRUG;

ARTICLE; DISPERSION; DRUG FORMULATION; DRY DEPOSITION; DRY POWDER; PARTICLE SIZE; PRIORITY JOURNAL;

ALBUTEROL; BRONCHODILATOR AGENTS; CHEMISTRY, PHARMACEUTICAL; LACTOSE; PARTICLE SIZE; POWDERS;

EID: 0033066810     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00021-6     Document Type: Article

References (18)

1. Baron, P.A., Willeke, K. (Eds.). Gas and particle motion. In: Aerosol Measurement: Principles, Techniques, and Applications. Van Nostrand Reinhold, New York, 1993, pp. 23-40.
2. French D.L., Edwards D.A., Niven R.W. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J. Aerosol Sci. 27:1996;769-783.
3. Ganderton D. The generation of respirable cloud from coarse powder aggregates. J. Biopharm Sci. 3:1992;101-105.
4. Ganderton D., Kassem N.M. Dry powder inhalers. Ganderton D., Jones T. Advances in Pharamaceutical Sciences. Vol. 6:1992;165-191 Academic Press, London.
5. Gonda I. Aerosols for delivery of therapeutic and diagnostic agents to the respiratory tract. CRC Rev. Ther. Drug Carrier Systems. 6:1990;273.
6. Hersey J.A. Ordered mixing: a new concept in powder mixing practice. Powder Technol. 11:1975;41-44.
7. Kaseem, N.M. Generation of deeply inspirable dry powders, Ph.D. thesis, University of London, 1990.
8. Lucas P., Anderson K., Staniforth J.N. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res. 15:1998;562-569.
9. Newman S.P., Clarke S.W. Therapeutic aerosols. I. Physical and practical considerations. Thorax. 38:1983;881-886.
10. Olsson B., Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J. Aerosol. Med. Deposition Clear. Eff. 7(suppl. 1):1994;S43-S47.
11. Otsuka A. Adhesive properties and related phenomena for powdered pharmaceuticals. Yakugaku Zasshi. 118:1998;127-142.
12. Srichana, G., Martin, G.P., Marriott, C., 1996. The effect of device design on drug deposition from dry powder inhaler fromulations determined in vitro at different flow rates. Proceedings of drug delivery to the lung VII, London, pp. 36-39.
13. Staniforth, J.N., 1996. Improvement in dry powder inhaler performance: surface passivation effects. Proceedings of Drug Delivery to the Lungs VII, London, pp. 86-89.
14. Steckel H., Müller B.W. In vitro evaluation of dry powder inhalers II: influence of carrier particle size and concentration on in vitro deposition. Int. J. Pharm. 154:1997;31-37.
15. Timsina M.P., Martin G.P., Marriott C., Ganderton D., Yianneskis M. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm. 101:1994;1-13.
16. Zeng, X.M., Tee, S.K., Martin, G.P., Marriott, C., 1996. Effects of mixing procedure and particle size distribution of carrier particles on the deposition of salbutamol sulphate from dry powder inhaler formulations. Proceedings of Drug Delivery to the Lung VII, London, pp. 40-43.
17. Zeng, X.M., Martin, G.P., Tee, S.K., Marriott, C., 1998. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int. J. Pharm. 176, 99-100.
18. Zimon A.D. Adhesion of Dust and Powder. 2nd ed:1982;Consultant Bureau, London.